Sector News

Merck to acquire German contract development company AmpTec

January 10, 2021
Life sciences

Merck has announced the acquisition of Germany-based, mRNA contract development and manufacturing organisation (CDMO) AmpTec.

The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.

Merck CEO and executive board chairman Stefan Oschmann said: “The success of mRNA-based vaccines for Covid-19 lays the path to accelerate the development of these therapeutics for many other diseases.

“By combining AmpTec’s PCR-based mRNA technology with Merck’s extensive expertise in lipids manufacturing, we are able to provide a truly differentiated and integrated offering across the mRNA value chain, which will significantly decrease supply chain complexity and enhance speed-to-market.”

Merck’s Life Science business sector’s SAFC portfolio includes lipids, which serve as major components for mRNA therapeutics formulation including for Covid-19 vaccines.

The company is partnering with over 50 vaccine manufacturers to aid in Covid-19 vaccine, treatment and service development and production efforts.

Another vital component of mRNA manufacturing is PCR technology. AmpTec utilises a distinguished PCR-based technology for producing mRNA.

As compared to others, PCR-based manufacturing technology has benefits such as homogeneity, purity, activity and flexibility, increased quality, better performance, as well as adaptable capping options to reach specific performance needs.

Apart from its specialisation in mRNA technology, AmpTec has a diagnostics business focused on making customised long RNAs and DNAs for in vitro diagnostics, which will complement existing Merck portfolio.

AmpTec managing directors and founders Guido Krupp and Peter Scheinert said: “AmpTec’s more than 40 employees are thrilled to join Merck and are confident that our PCR-based technology and combined expertise will allow us to offer customers innovative technologies, products and services to help advance life-enhancing therapeutics.”

Financial terms of the deal remain undivulged.

Last November, Merck signed a definitive agreement to acquire all outstanding shares of clinical-stage biopharmaceutical firm OncoImmune through a subsidiary, for an upfront payment of $425m in cash.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend